Review of the use of topotecan in ovarian carcinoma.

Abstract:

:Ovarian cancer is the fifth leading cause of cancer deaths in women. The majority of patients present with advanced disease and relapse after first-line platinum-based chemotherapy; therefore, many proceed to treatment with salvage chemotherapy. Currently available treatment options are generally no longer curative in the relapse setting; hence, the emphasis of treatment is towards disease control and palliation of symptoms. There are several agents available for the treatment of relapsed ovarian carcinoma, of which topotecan is one of the most widely studied and characterised. This review aims to evaluate the role of topotecan in the management of this disease by considering the properties of the compound, the clinical efficacy in Phase II and III studies, its role in first- and second-line treatment and alternative dosing strategies to overcome toxicity.

authors

Ahmad T,Gore M

doi

10.1517/14656566.5.11.2333

keywords:

subject

Has Abstract

pub_date

2004-11-01 00:00:00

pages

2333-40

issue

11

eissn

1465-6566

issn

1744-7666

pii

EOP051114

journal_volume

5

pub_type

杂志文章,评审
  • A pharmacogeneticist's look at drug effects and the drug development process: an overview.

    abstract::This paper describes the functional roles of the closely related pharmacogenetic and pharmacogenomic sciences in medicine. Firstly, they provide means for a better understanding of the function of drugs, and particularly of the differences of drug action between individuals and also between racially categorised popula...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.8.1299

    authors: Kalow W

    更新日期:2005-07-01 00:00:00

  • In diabetic foot infections antibiotics are to treat infection, not to heal wounds.

    abstract:INTRODUCTION:Diabetic foot ulcers, especially when they become infected, are a leading cause of morbidity and may lead to severe consequences, such as amputation. Optimal treatment of these diabetic foot problems usually requires a multidisciplinary approach, typically including wound debridement, pressure off-loading,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1021780

    authors: Abbas M,Uçkay I,Lipsky BA

    更新日期:2015-04-01 00:00:00

  • Pediatric HIV: new opportunities to treat children.

    abstract:BACKGROUND:Treating HIV-infected children remains a challenge due to a lack of treatment options, appropriate drug formulations and, in countries with limited resources, insufficient access to diagnostic tests and treatment. OBJECTIVE:To summarize current data concerning new opportunities to improve the treatment of H...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903012377

    authors: Van der Linden D,Callens S,Brichard B,Colebunders R

    更新日期:2009-08-01 00:00:00

  • Orlistat in the treatment of obesity.

    abstract::Orlistat (Xenical, Hoffmann-La Roche) is a powerful inhibitor of gastrointestinal lipase and as such, reduces fat absorption. Unlike other weight-reducing drugs it is minimally absorbed and has no effects in the CNS. Orlistat is indicated for patients with a body mass index (BMI) of at least 30 kg/m2 or 28 kg/m2 in th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.4.841

    authors: Ballinger A

    更新日期:2000-05-01 00:00:00

  • Dapagliflozin for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Despite the availability of many antihypreglycemic agents, many patients with type 2 diabetes (T2DM) fail to achieve the glycemic treatment goal, primarily due to progressive beta-cell dysfunction, and increased risk of hypoglycemia. AREAS COVERED:The aim of the present article is to review the efficacy a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.812632

    authors: Abdul-Ghani MA,DeFronzo RA

    更新日期:2013-08-01 00:00:00

  • Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?

    abstract::The aim of this review is to provide a rationale for evaluating thiazolidinediones (TZDs) as putative treatments for cognitive deficits in individuals with mood disorders. A MedLine search of all English-language articles published between January 1966 and August 2006 was conducted. The search terms were: the non-prop...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.11.1615

    authors: McIntyre RS,Soczynska JK,Woldeyohannes HO,Lewis GF,Leiter LA,MacQueen GM,Miranda A,Fulgosi D,Konarski JZ,Kennedy SH

    更新日期:2007-08-01 00:00:00

  • Erectile dysfunction, cardiovascular diseases and depression: interaction of therapy.

    abstract::Several studies have revealed the intimate associations between erectile dysfunction (ED), ischemic heart disease (IHD) and depression. Whether the physicians should also screen for the other two components when a patient presents with one component of this triad is still an important question to be answered. These th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903089326

    authors: El-Sakka AI,Shamloul R,Yassin AA

    更新日期:2009-09-01 00:00:00

  • The pharmacological management of cardiovascular disease in people living with HIV (PLWH).

    abstract::ABSTARCT Introduction: Cardiovascular disease (CVD) continues to be an essential cause of morbidity and mortality among people living with human immunodeficiency virus infection (PLWH). Since the bulk of cardiovascular risk (CVR) factors are shared between PLWH and the general population, prevention and treatment stra...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1856075

    authors: Corbacho N,Mur I,Molas ME,Vidal F,Domingo P

    更新日期:2021-01-04 00:00:00

  • Abatacept: a novel treatment for rheumatoid arthritis.

    abstract::Rheumatoid arthritis (RA) is a chronic, autoimmune disease that has traditionally been treated with non-biologic and biologic disease-modifying antirheumatic drugs (DMARDs). Although these agents have become firmly established as effective RA treatments, some patients do not have an adequate response. The recent appro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.14.2371

    authors: Lundquist LM

    更新日期:2007-10-01 00:00:00

  • Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments.

    abstract::Introduction: Body dysmorphic disorder is a debilitating disorder that often presents with significant delusionality, low insight, and both medical and psychiatric comorbidities, presenting a challenge for treatment and long-term management. Its typically chronic course requires that therapy be continued indefinitely,...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1610385

    authors: Dong N,Nezgovorova V,Hong K,Hollander E

    更新日期:2019-07-01 00:00:00

  • Pharmacokinetic profile of a new formulation of injection diclofenac designed for intradeltoid use.

    abstract:OBJECTIVE:Injection diclofenac sodium available at present as a 3-ml formulation is administered intragluteally. Standard needles may not reach the gluteus maximus muscle in many cases, especially in obese patients. Alternative sites like the deltoid have been suggested to be more suitable for these patients. Diclofena...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560902732066

    authors: Ojha A,Shep D,Nivsarkar M,Patel S,Jaiswal V,Padh H

    更新日期:2009-03-01 00:00:00

  • Therapeutic choices in convulsive status epilepticus.

    abstract:INTRODUCTION:Convulsive status epilepticus (SE) is one of the most frequent and severe neurological emergencies in both adults and children. A timely administration of appropriate antiepileptic drugs (AEDs) can stop seizures early and markedly improve outcome. AREAS COVERED:The main treatment strategies for SE are rev...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.997212

    authors: Sánchez Fernández I,Loddenkemper T

    更新日期:2015-03-01 00:00:00

  • Apomorphine in the treatment of Parkinson disease and other movement disorders.

    abstract:BACKGROUND:Apomorphine, a medication that has been studied intensively over the years, is available in the US as intermittent subcutaneous injections for treatment of 'off' motor states in Parkinson disease. OBJECTIVE:The clinical literature is summarized with particular focus on randomized controlled studies of apomo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902828344

    authors: Gunzler SA

    更新日期:2009-04-01 00:00:00

  • Oral valproic acid for epilepsy--long-term experience in therapy and side effects.

    abstract::Valproic acid (VPA) is considered to be a drug of first choice and one of the most frequently-prescribed antiepileptic drugs worldwide for the therapy of generalized and focal epilepsies, including special epileptic. It is a broad-spectrum antiepileptic drug and is usually well tolerated. Rarely, serious complications...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.2.285

    authors: Gerstner T,Bell N,König S

    更新日期:2008-02-01 00:00:00

  • An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.

    abstract:INTRODUCTION:Moderate-to-severe AD burdens a large proportion of AD patients and may represent an inadequacy of treatment options available for resistant disease. AREAS COVERED:This review provides an overview of the therapies for moderate-to-severe AD in late-stage development and in the clinic, and focuses on barici...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,评审

    doi:10.1080/14656566.2020.1739268

    authors: Mendes JT,Balogh EA,Strowd LC,Feldman SR

    更新日期:2020-06-01 00:00:00

  • Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.

    abstract:INTRODUCTION:In this review, the authors describe medications in phase III of clinical development for schizophrenia and schizoaffective disorder, and provide an opinion on how current treatment can be improved in the near future. AREAS COVERED:Recent (post 2013) phase III clinical trials of schizophrenia-targeted the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1149164

    authors: Garay RP,Citrome L,Samalin L,Liu CC,Thomsen MS,Correll CU,Hameg A,Llorca PM

    更新日期:2016-01-01 00:00:00

  • A review of olanzapine pamoate.

    abstract:INTRODUCTION:Olanzapine long-acting injection (OLAI), or olanzapine pamoate , is one of three second generation (SGA) antipsychotics now available in a long-acting formulation. OLAI is a microcrystalline salt of pamoic acid and olanzapine suspended in an aqueous solution that slowly dissociates into the separate compon...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.2012.686169

    authors: Chue P,Chue J

    更新日期:2012-08-01 00:00:00

  • Evaluation of injection force of three insulin delivery pens.

    abstract:OBJECTIVE:Reduced injection force is among the modifications to the Next Generation FlexPen (NGFP). This force was compared with two other prefilled pens: SoloStar (SS) and KwikPen (KP). RESEARCH DESIGN/METHODS:The injection force of the pens was measured, with either a BD Micro-Fine 31G thin-wall needle, or a NovoFin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560903018929

    authors: Asakura T,Seino H,Kageyama M,Yohkoh N

    更新日期:2009-06-01 00:00:00

  • Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.

    abstract::Poor therapeutic adherence is a major issue faced by physicians today. This paper summarizes the adherence rates with oral bisphosphonate (OBP) treatment in clinical practice and their impact on clinical outcomes. Studies systematically demonstrated that overall compliance and persistence with OBPs among osteoporotic ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903140533

    authors: Rabenda V,Hiligsmann M,Reginster JY

    更新日期:2009-10-01 00:00:00

  • Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary.

    abstract::Peglyated liposomal doxorubicin was developed to maintain or enhance the demonstrated antineoplastic effects of doxorubicin, while improving the toxicity profile associated with this important cytotoxic agent. Accumulating clinical data have confirmed the activity of pegylated liposomal doxorubicin in cancers of the b...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.7.11.1469

    authors: Markman M

    更新日期:2006-08-01 00:00:00

  • The optimal pharmacological formula for percutaneous coronary intervention.

    abstract:INTRODUCTION:Adjunctive pharmacotherapy is of key importance in determining the outcomes of percutaneous coronary intervention (PCI). In parallel, there has been an increasing body of evidence indicating that the aggressive management of coronary risk factors and changes in lifestyle behavior yield additional positive ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.546345

    authors: Capodanno D,Tamburino C,Dangas G

    更新日期:2011-05-01 00:00:00

  • From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study.

    abstract:PURPOSE:To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). METHODS:Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1517/14656566.2011.589384

    authors: Rossi GC,Pasinetti GM,Sandolo F,Bordin M,Bianchi PE

    更新日期:2011-11-01 00:00:00

  • Pharmacological management of paracoccidioidomycosis.

    abstract::A systemic and endemic emerging mycosis in Latin America, paracoccidioidomycosis, is characterised by its chronicity and by the severity of the disseminated form in healthy individuals, as well as in immunocompromised individuals co-infected with HIV, resulting, in the latter, in a mortality rate in the range of 30 - ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.3.385

    authors: Yasuda MA

    更新日期:2005-03-01 00:00:00

  • Delaying surgery with chemotherapy for osteosarcoma of the extremities.

    abstract::Osteosarcoma is the most frequent primary cancer of bone. When treated by surgery alone, it is almost invariably followed by metastatic dissemination and death. This dismal prognosis can be improved dramatically by including chemotherapy in an interdisciplinary regimen. Today, two-thirds of patients with localised ext...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.6.1243

    authors: Bielack SS,Machatschek JN,Flege S,Jürgens H

    更新日期:2004-06-01 00:00:00

  • Current strategies for the treatment of complicated intraabdominal infections.

    abstract:INTRODUCTION:Complicated intraabdominal infections (cIAIs) are a common cause of infection-related morbidity and mortality in hospitalized patients and present many challenges unique from other serious infections. cIAIs are generally polymicrobial in nature; however, controversy exists around the pathogenicity of some ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.821109

    authors: Skrupky LP,Tellor BR,Mazuski JE

    更新日期:2013-10-01 00:00:00

  • Management of hepatitis C virus-related arthritis.

    abstract::In recent years, hepatitis C virus-related arthritis (HCVrA) has been recognised as an autonomous rheumatic disorder. Two subsets of the disease have been identified: a polyarthritis involving small joints that resembles rheumatoid arthritis, but is usually milder, and a mono-oligoarthritis that shows an intermittent ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.1.27

    authors: Palazzi C,Olivieri I,Cacciatore P,Pennese E,D'Amico E

    更新日期:2005-01-01 00:00:00

  • Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?

    abstract:INTRODUCTION:Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia. AREAS COVERED:The effec...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.557359

    authors: Rizzo M,Corrado E,Patti AM,Rini GB,Mikhailidis DP

    更新日期:2011-03-01 00:00:00

  • Pharmacotherapy for the treatment of vaginal atrophy.

    abstract:INTRODUCTION:Despite its frequency, recognition and therapy of vulvovaginal atrophy (VVA) remain suboptimal. Wet mount microscopy, or vaginal pH as a proxy, allows VVA diagnosis in menopause, but also in young contraception users, after breast cancer, or postpartum. Intravaginal low dose estrogen product is the main th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1574752

    authors: Donders GGG,Ruban K,Bellen G,Grinceviciene S

    更新日期:2019-05-01 00:00:00

  • Opioids in the treatment of postoperative pain: old drugs with new options?

    abstract::New approved options with opioids in the postoperative setting may include new ways of administration, new combinations with other drugs and new opioid drugs. Newly approved devices for administration include sublingual sufentanil dispenser and transdermal iontophoretic fentanyl, with the purpose of almost mimicking t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2014.879292

    authors: Raeder J

    更新日期:2014-03-01 00:00:00

  • Pharmacotherapy of large B-cell lymphoma.

    abstract:BACKGROUND:Constituting approximately 30% of lymphoid malignancies, diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma in adults worldwide. The clinical and biologic heterogeneity that exists in DLBCL suggests that this entity might actually be comprised of several distinct neoplasms that coul...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.13.2247

    authors: Escalón MP,Lossos IS

    更新日期:2008-09-01 00:00:00